Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 30, 2020 at 11:22 PM.

  1. #1 cafead, Sep 30, 2020 at 11:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring that will cut 40 percent of its staff, splitting the remaining workforce into two distinct business units.

    article source
     
    Quote

Reply to Thread